Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
By F. Shepherd, J. Dancey, R. Ramlau, K. Mattson, R. Gralla, M. O'Rourke, N. Levitan, L. Gressot, M. Vincent, R. Burkes and 3 more. Journal of Clinical Oncology, 2000
2,210 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/d1288ae0af127b56470f2c2f5e0439258fb095aa
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. (2013, neutral): “Elevated aminotransferase levels† 66 (38) 27 (16)¶ 25 (15) 4 (2)”
- Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. (2006, background): “Selected second- and third-line treatment strategies, currently single-agent regimens, can further improve survival duration [16, 17].”
- Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. (2003, neutral): “Symptom improvement rate [95% CI] 44 (43) [33-53] 40 (35) [26-45] 84 (39) [32-45] .”
- Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer (2015, neutral): “Unknown or not reported 5 (2) 10 (3) 15 (3)”
- Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, methodology): “Docetaxel has shown improved efficacy compared with BSC in randomised trials with a significant improvement in OS in the TAX 320 trial for those patients who received docetaxel at a dose of 75 mg/m(2) every 3 weeks [152, 153].”
- Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. (2015, background): “Both docetaxel (70) and pemetrexed (71) are approved active agents in the second-line setting, but more therapeutic options were needed, especially for those unable to have further chemotherapy.”
- American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. (2009, background): “It found a significant survival benefit to docetaxel versus best supportive care.(102,103)”